The first step on our quest to early detection at the point-of-care is commercializing our IONIQ ProLung Test, which has been designated a Breakthrough Device by the US FDA for its life-enhancing potential. We then plan to commercialize our IONIQ Breast Test, which has entered feasibility testing.
By following the principles of scientific process, IONIQ Sciences will amass vast amounts of valuable clinical data that we are using to develop and commercialize the first ever FDA cleared Multi-Cancer Screen.